Intra-Cellular Therapies Revenue and Competitors
Estimated Revenue & Valuation
- Intra-Cellular Therapies's estimated annual revenue is currently $70.6M per year.
- Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
- Intra-Cellular Therapies's estimated revenue per employee is $83,145
- Intra-Cellular Therapies's total funding is $674.1M.
- Intra-Cellular Therapies's current valuation is $3.5B. (January 2022)
Employee Data
- Intra-Cellular Therapies has 849 Employees.
- Intra-Cellular Therapies grew their employee count by 38% last year.
Intra-Cellular Therapies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman & CEO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | Associate VP, Clinical Development | Reveal Email/Phone |
4 | Executive Director, Accounting | Reveal Email/Phone |
5 | Executive Director, Head Sales Operations | Reveal Email/Phone |
6 | SVP, Chief Compliance Officer | Reveal Email/Phone |
7 | VP, Marketing | Reveal Email/Phone |
8 | VP, Drug Safety and Pharmacovigilance | Reveal Email/Phone |
9 | SVP | Reveal Email/Phone |
10 | SVP, Head Clinical Development | Reveal Email/Phone |
Intra-Cellular Therapies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.1M | 65 | 7% | N/A | N/A |
#2 | $354.3M | 484 | -2% | $567.1M | N/A |
#3 | $347.1M | 1727 | -8% | N/A | N/A |
#4 | $8.8M | 44 | 13% | N/A | N/A |
#5 | $6M | 30 | 11% | N/A | N/A |
#6 | $46.6M | 232 | 4% | N/A | N/A |
#7 | $6.6M | 33 | -3% | N/A | N/A |
#8 | $11.3M | 56 | 12% | N/A | N/A |
#9 | $168.8M | 840 | 46% | N/A | N/A |
#10 | $12.3M | 61 | -21% | N/A | N/A |
What Is Intra-Cellular Therapies?
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0
keywords:Biotechnology,Healthcare,Pharmaceuticals
$674.1M
Total Funding
849
Number of Employees
$70.6M
Revenue (est)
38%
Employee Growth %
$3.5B
Valuation
N/A
Accelerator
Intra-Cellular Therapies News
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...
Piper Sandler had initiated Intra-Cellular Therapies (NASDAQ:ITCI) with a hold rating saying that the current share price reflects...
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...
It may be almost the end of the year, but the FDA’s stamina for approvals has persevered. On Monday, Intra-Cellular Therapies secured the regulator’s blessing for its antipsychotic drug, Caplyta, despite two late-stage schizophrenia studies that left much to be desired. But as is custom with mo ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $172.3M | 849 | 1% | N/A |
#2 | $214.5M | 851 | N/A | N/A |
#3 | $75M | 851 | 12% | N/A |
#4 | $297.9M | 851 | 0% | N/A |
#5 | $4.8M | 852 | 27% | $207M |
Intra-Cellular Therapies Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-02-03 | $100.2M | Undisclosed | Leerink Partners LLC | Article |
| 2014-02-06 | $115.3M | Undisclosed | Leerink Partners LLC | Article |
| 2015-03-09 | $106.5M | Undisclosed | Leerink Partners LLC | Article |
| 2015-03-13 | $121.4M | Undisclosed | Leerink Partners LLC, | Article |
| 2017-09-29 | $150.0M | Undisclosed | J.P. Morgan Securities LLC | Article |